Loading
EI
Enfusion, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by ICONIQ Strategic Partners V, L.P., was filed 27 Oct 2021.
Enfusion, Inc.: what insiders have been doing
Every trade that managers of Enfusion, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Business Services sector. The past year has been quiet: not a single insider filing for Enfusion, Inc. The previous disclosure was published on 23 April 2025.
Our records for Enfusion, Inc. go back to 2021, with 2 purchases and 76 sales on the open market in total.
Elsewhere in the same sector, our signals recently picked up insider purchases at ELIS and GL Events. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
251
Thresholds
n/a
Buy Volume
€18M
2 ops. · all time
Sell Volume
€131M
76 ops. · all time
Who traded when
BuySaleNeal Pawar5 sales
Valeria Gutowski5 sales
Bradley Herring4 sales
Bronwen Bastone3 sales
Matthew Campobasso3 sales
Oleg Movchan3 sales
+1 other insider
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$173.6M
Gross profitUS$117.7M68% margin
Net incomeUS$2.4M1.4% margin
Last declaration on 23 April 2025
Declarations251 total
722,707 sharesClass A Common StockSEC:0000950170-25-057455:1
7,748,000 sharesClass A Common StockSEC:0000950170-25-057455:2
722,707 sharesClass A Common StockSEC:0000950170-25-057454:1
7,748,000 sharesClass A Common StockSEC:0000950170-25-057454:2
538,887 sharesClass A Common StockSEC:0000950170-25-057455:0
538,887 sharesClass A Common StockSEC:0000950170-25-057454:0
51,808 sharesClass A Common StockSEC:0001104659-25-036909:1
230,039 sharesClass A Common StockSEC:0001104659-25-036909:2
250,000 sharesClass A Common StockSEC:0001104659-25-036909:3
100,000 sharesClass A Common StockSEC:0001104659-25-036909:4
45,799 sharesClass A Common StockSEC:0001104659-25-036900:1
501,695 sharesClass A Common StockSEC:0001104659-25-036913:1
580,000 sharesClass A Common StockSEC:0001104659-25-036913:2
216,357 sharesClass A Common StockSEC:0001104659-25-036912:1
15,864 sharesClass A Common StockSEC:0001104659-25-036890:0
161,893 sharesClass A Common StockSEC:0001104659-25-036890:1
35,294 sharesClass A Common StockSEC:0001104659-25-036890:2
31,303 sharesClass A Common StockSEC:0001104659-25-036901:1
60,716 sharesClass A Common StockSEC:0001104659-25-036895:0
41,675 sharesClass A Common StockSEC:0001104659-25-036896:0
25,147 sharesClass A Common StockSEC:0001104659-25-036900:0
108,332 sharesClass A Common StockSEC:0001104659-25-036912:0
57,925 sharesClass A Common StockSEC:0001104659-25-036902:0
135,613 sharesClass A Common StockSEC:0001104659-25-036913:0
175,572 sharesClass A Common StockSEC:0001104659-25-036905:0
25 of 251 declarations
About Enfusion, Inc.
Enfusion, Inc. (ticker: ENFN) is a U.S.-based company listed on the NYSE/NASDAQ in the United States, focused on technology and services for the investment management industry. Founded in 1997 and headquartered in Chicago, Illinois, Enfusion has built its business around a cloud-based software platform designed to support the full investment lifecycle, from the front office through the back office. Its customer base is primarily made up of hedge funds, asset managers, multi-asset investment firms, family offices, trading teams, operations groups, and compliance functions.
The company’s core offering is an integrated platform that combines several functions that are often handled by separate systems. Enfusion provides a Portfolio Management System that can generate a real-time investment book of record, with valuation, risk, and portfolio analytics tools. It also offers an Order and Execution Management System, enabling portfolio managers, traders, analysts, and compliance teams to create, track, and control orders across multiple asset classes. In addition, the platform includes reporting, analytics, workflow, and automation capabilities designed to streamline investment operations. This front-to-back integration is one of Enfusion’s main competitive differentiators in a market that is often fragmented across multiple vendors.
Read moreShow less
From a competitive standpoint, Enfusion operates in a segment supported by the secular digitization of buy-side workflows, tighter regulatory expectations, and the growing need for real-time consolidated data. Its proposition is centered on a single cloud-native platform intended to reduce operational complexity while improving visibility into positions, risk, and trade activity. The company positions itself as a provider of institutional-grade tools for globally distributed investment teams.
Geographically, Enfusion operates from the United States but serves an international client base, which fits the global nature of capital markets. Public filings indicate that the company maintains investor-relations and reporting resources through its corporate website. Recent investor-relevant developments include its 2025 annual report, which highlights continued investment in technology, compliance, and the obligations associated with being a public company. Recent SEC Form 4 filings also indicate ongoing insider transaction activity, though such activity should always be interpreted carefully and in context. For French-speaking investors, ENFN offers exposure to the structural trend toward automation in asset management, through a U.S. NYSE/NASDAQ-listed business in the business services and financial-technology space.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
